ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.
[R]-ESHAP consists of:
- (R)ituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
- (E)toposide, an epipodofyllotoxin topoisomerase inhibitor
- (S)olu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
- (H)igh-dose (A)ra-C - cytarabine
- (P)latinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
|(R)ituximab||375 mg/m2||IV infusion||Day 0|
|(E)toposide||40 mg/m2||IV infusion over 1 hr||Days 1-4|
|(S)olu-Medrol - Methylprednisolone||500 mg||IV bolus over 15 min||Days 1-5|
|(H)igh-dose (A)ra-C — cytarabine||2000 mg/m2||IV infusion over 2 hrs||Day 5|
|Platinol (cisplatin)||25 mg/m2||IV continuous infusion over 24 hrs||Days 1-4|